GATA‐binding protein 3 enhances the utility of gross cystic disease fluid protein‐15 and mammaglobin A in triple‐negative breast cancer by immunohistochemistry

We have demonstrated previously that gross cystic disease fluid protein‐15 (GCDFP‐15) and mammaglobin A (MAM) are of limited utility in triple‐negative breast cancer (TNBC). GATA‐binding protein 3 (GATA‐3) is an emerging breast‐associated immunohistochemical (IHC) marker with limited data in TNBC. Here, we examined GATA‐3 expression in TNBC in comparison with GCDFP‐15 and MAM.

[1]  Yunni-Yi Chen,et al.  Diagnostic utility and sensitivities of GATA3 antibodies in triple-negative breast cancer. , 2014, Human pathology.

[2]  D. Dabbs,et al.  Semiquantitative GATA-3 immunoreactivity in breast, bladder, gynecologic tract, and other cytokeratin 7-positive carcinomas. , 2014, American journal of clinical pathology.

[3]  G. Hortobagyi,et al.  Which threshold for ER positivity? a retrospective study based on 9639 patients. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  J. Prichard,et al.  Immunohistochemical evaluation of GATA-3 expression in ER-negative breast carcinomas. , 2014, American journal of clinical pathology.

[5]  T. Gudewicz,et al.  Cutaneous and mammary apocrine carcinomas have different immunoprofiles. , 2014, Human pathology.

[6]  Markku Miettinen,et al.  GATA3: A Multispecific But Potentially Useful Marker in Surgical Pathology A Systematic Analysis of 2500 Epithelial and Nonepithelial Tumors , 2014, The American journal of surgical pathology.

[7]  J. Epstein,et al.  GATA3 expression in paragangliomas: a pitfall potentially leading to misdiagnosis of urothelial carcinoma , 2013, Modern Pathology.

[8]  N. Ordóñez.  Value of GATA3 Immunostaining in Tumor Diagnosis: A Review , 2013, Advances in anatomic pathology.

[9]  Marc K Halushka,et al.  GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas. , 2013, Human pathology.

[10]  J. Bishop,et al.  GATA3 Immunohistochemical Expression in Salivary Gland Neoplasms , 2013, Head and Neck Pathology.

[11]  K. Hunt,et al.  Gross cystic disease fluid protein‐15 and mammaglobin A expression determined by immunohistochemistry is of limited utility in triple‐negative breast cancer , 2013, Histopathology.

[12]  J. McKenney,et al.  Selective immunohistochemical markers to distinguish between metastatic high-grade urothelial carcinoma and primary poorly differentiated invasive squamous cell carcinoma of the lung. , 2012, Archives of pathology & laboratory medicine.

[13]  J. Epstein,et al.  Utility of GATA3 Immunohistochemistry in Differentiating Urothelial Carcinoma From Prostate Adenocarcinoma and Squamous Cell Carcinomas of the Uterine Cervix, Anus, and Lung , 2012, The American journal of surgical pathology.

[14]  M. Wilkerson,et al.  Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas. , 2012, American journal of clinical pathology.

[15]  F. Grosveld,et al.  Gata3-deficient mice develop parathyroid abnormalities due to dysregulation of the parathyroid-specific transcription factor Gcm2. , 2010, The Journal of clinical investigation.

[16]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[17]  D. Nonaka,et al.  A study of immunohistochemical differential expression in pulmonary and mammary carcinomas , 2010, Modern Pathology.

[18]  R. Tavares,et al.  GCDFP-15 Positive and TTF-1 Negative Primary Lung Neoplasms: A Tissue Microarray Study of 381 Primary Lung Tumors , 2009, Applied immunohistochemistry & molecular morphology : AIMM.

[19]  E. Lam,et al.  Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours , 2009, Breast Cancer Research.

[20]  B. Spaulding,et al.  Mammaglobin, a valuable diagnostic marker for metastatic breast carcinoma. , 2009, International journal of clinical and experimental pathology.

[21]  J. Higgins,et al.  Expression of the Urothelial Differentiation Markers GATA3 and Placental S100 (S100P) in Female Genital Tract Transitional Cell Proliferations , 2009, The American journal of surgical pathology.

[22]  Z. Werb,et al.  GATA-3 and the regulation of the mammary luminal cell fate. , 2008, Current opinion in cell biology.

[23]  Robert J. Marinelli,et al.  Placental S100 (S100P) and GATA3: Markers for Transitional Epithelium and Urothelial Carcinoma Discovered by Complementary DNA Microarray , 2007, The American journal of surgical pathology.

[24]  Marie-Liesse Asselin-Labat,et al.  Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation , 2007, Nature Cell Biology.

[25]  H. Iwata,et al.  Breast-specific expression of MGB1/mammaglobin: an examination of 480 tumors from various organs and clinicopathological analysis of MGB1-positive breast cancers , 2007, Modern Pathology.

[26]  Zena Werb,et al.  GATA-3 Maintains the Differentiation of the Luminal Cell Fate in the Mammary Gland , 2006, Cell.

[27]  Florian Fritzsche,et al.  Expression analysis of mammaglobin A (SCGB2A2) and lipophilin B (SCGB1D2) in more than 300 human tumors and matching normal tissues reveals their co-expression in gynecologic malignancies , 2006, BMC Cancer.

[28]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[29]  M. Busslinger,et al.  Pax2/8-regulated Gata3 expression is necessary for morphogenesis and guidance of the nephric duct in the developing kidney , 2006, Development.

[30]  Debashis Ghosh,et al.  Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. , 2005, Cancer research.

[31]  F. Müller,et al.  Essential role of Gata transcription factors in sympathetic neuron development , 2004, Development.

[32]  Hyunsoo Kim,et al.  Mammaglobin expression in lymph nodes is an important marker of metastatic breast carcinoma. , 2003, Archives of pathology & laboratory medicine.

[33]  C. Kaufman,et al.  GATA-3: an unexpected regulator of cell lineage determination in skin. , 2003, Genes & development.

[34]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[35]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[37]  R. Weigel,et al.  GATA‐3 is expressed in association with estrogen receptor in breast cancer , 1999, International journal of cancer.

[38]  J. Leiden,et al.  Transcription factor GATA-3 is required for development of the T-cell lineage , 1996, Nature.

[39]  M. Wick,et al.  Gross cystic disease fluid protein-15 as a marker for breast cancer: immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin. , 1989, Human pathology.

[40]  D. Dabbs,et al.  Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity. , 2007, American journal of clinical pathology.

[41]  James Douglas Engel,et al.  Gata3 loss leads to embryonic lethality due to noradrenaline deficiency of the sympathetic nervous system , 2000, Nature Genetics.